Related Experiment Video
Updated: Jan 7, 2026
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Biomarkers
Shorena Janelidze1, Lyduine E Collij2, Niklas Mattsson-Carlgren3,4
1Clinical Memory Research Unit, Lund University, Lund, NA, Sweden.
Background:
Plasma biomarkers of Alzheimer's disease (AD) could improve the prognostic evaluation of individuals with Down syndrome (DS) in both clinical practice and trials. In this study, we aimed to identify plasma biomarkers that best predict changes in AD-related tau pathology and cognitive decline in DS.
Method:
The study comprised 258 adults with DS from the longitudinal ABC-DS study, with plasma phospho-tau217 (pTau217), glial fibrillary acidic protein (GFAP), amyloid-β (Aβ)42/40, neurofilament light (NfL), and total-tau (tTau) assessments (Table-1). Associations of plasma biomarkers with slopes of global cognitive functioning (Down Syndrome Mental Status Examination scores [DS-MSE]) and tau-PET ([18F]flortaucipir uptake in temporal meta-region) were examined using linear regression models. Plasma biomarker associated risk of progression to dementia was determined using survival analysis.
Result:
Baseline pTau217, GFAP, NfL, and tTau were all individually associated with longitudinal change of DS-MSE (pTau217: β=-0·38; GFAP: β=-0·40; NfL: β=-0·34; tTau: β=-0·19; p <0·002, Figure 1) and progression to dementia (pTau217: HR=3·95, p <0·001; GFAP: HR=3·87, p <0·001; NfL: HR=2·05, tTau: HR=1·75; p <0·008). However, in a combined model, only pTau217 remained associated with cognitive deterioration (β=-0·27, p <0·001) and progression to dementia (HR=3·47, p <0·001, Figure 2). Associations with tau-PET slopes (n = 62) were significant for baseline plasma pTau217 (β=0·29, p = 0·02) and GFAP (β=0·42, p = 0·002; Figure 3) individually and in the combined model (pTau217: β=0·24, p = 0·04; GFAP, β=0·39, p = 0·005). Longitudinal change of plasma pTau217 levels correlated with longitudinal change of cognition (β=-0·43, p <0·001) and tau-PET (β=0·83, p <0·001).
Conclusion:
Baseline plasma pTau217 predicted subsequent decline in global cognition and progression to dementia, whereas both pTau217 and GFAP were associated with an increase in tau burden. Longitudinal increase in pTau217 levels was associated with accelerated cognitive decline and tau deposition. These findings suggest that blood pTau217, potentially together with GFAP, could support the prognostic workup of AD in individuals with DS in both clinical practice and trials.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...